Procalcitonin Predicts Infection Severity and Mortality in Pediatric Febrile Neutropenia, Suggests Study
A recent prospective analysis published in Indian Pediatrics in March 2025 highlights procalcitonin (PCT) as a powerful biomarker that effectively distinguishes between different infection types (MDI, CDI, and NF) in pediatric cancer patients facing febrile neutropenia. Crucially, PCT also serves as a reliable predictor of 30-day mortality, offering a vital tool to better manage and safeguard these vulnerable children.
Identifying the precise infectious etiology in immunosuppressed pediatric oncology patients remains a critical clinical challenge, prompting investigators led by Jagdish Prasad Meena and colleagues. To improve risk stratification, the study aimed to evaluate and compare the diagnostic performance of a secondary biomarker, proadrenomedullin (ProADM), alongside PCT for differentiating infection types, while concurrently assessing their prognostic value for identifying adverse clinical outcomes in this high-risk population.
Therefore, the prospective analysis measured PCT and ProADM levels on days 1, 3, and 7 in 345 pediatric cancer patients with febrile neutropenia to diagnose infection types and predict adverse outcomes like 30-day mortality. Patients who had received antibiotics within the previous 14 days were excluded to ensure accurate baseline evaluations.
Key Clinical Findings of the Study Includes:
Diagnostic Differentiation: Investigators observed that PCT concentrations in children suffering from MDI were significantly more elevated than those presenting with CDI on both day 1 (P = 0.031) and day 7 (P < 0.001).
Predictive Cut-offs: Analysis revealed that a day 1 PCT threshold of ≥ 0.21 ng/mL successfully predicted MDI (P = 0.041), yielding a diagnostic sensitivity of 77%, a specificity of 44%, and an area under the receiver operating characteristic curve of 0.601. Mortality Indicator: Research established that a PCT concentration reaching ≥ 1.77 ng/mL by day 7 acted as a robust, independent prognostic predictor for day-30 mortality among the affected pediatric cohort.
Biomarker Limitations: Data indicated that, unlike PCT, the ProADM biomarker failed to successfully differentiate between the MDI and CDI classifications in the studied clinical population.
Therapeutic Trajectory: Findings highlighted that baseline measurements of either PCT or ProADM on day 1 did not reliably predict the subsequent clinical necessity for escalating to second-line antibiotic therapies.
The results suggest that PCT serves as an effective diagnostic tool capable of differentiating between MDI, CDI, and NF in pediatric oncology patients presenting with FN. Furthermore, the data reinforce its prognostic value, as a day 7 PCT level of ≥ 1.77 ng/mL effectively anticipates 30-day mortality risk.
For healthcare professionals managing pediatric cancers, incorporating routine longitudinal PCT monitoring during the initial week of FN episodes may provide a helpful adjunctive method to stratify infectious risks and better anticipate severe complications.
Although the currently available text does not explicitly detail the specific limitations of this investigation or outline formal recommendations for future research, the initial findings gently highlight the ongoing necessity for comprehensive studies to further validate biomarker utility in optimizing pediatric cancer care protocols.
Reference
Meena, J. P., Makkar, H., Gupta, A. K., Halder, A., Sharma, P., & Seth, R. (2025). Diagnostic and Prognostic Performance of Proadrenomedullin Versus Procalcitonin in Children with Cancer and Febrile Neutropenia. Indian Pediatrics, 62, 181–188.
